Fructus Amomi Cardamomi Extract Inhibits Coxsackievirus-B3 Induced Myocarditis in a Murine Myocarditis Model
2
조회
0
다운로드
8
인용
0
참고문헌
키워드
초록
Coxsackievirus B3 (CVB3) is the main cause of acute myocarditis and dilated cardiomyopathy. Plant extracts are considered as useful materials to develop new antiviral drugs. We had previously selected candidate plant extracts, which showed anti-inflammatory effects. We examined the antiviral effects by using a HeLa cell survival assay. Among these extracts, we chose the Amomi Cardamomi (Amomi) extract, which showed strong antiviral effect and preserved cell survival in CVB3 infection. We investigated the mechanisms underlying the ability of Amomi extract to inhibit CVB3 infection and replication. HeLa cells were infected by CVB3 with or without Amomi extract. Erk and Akt activities, and their correlation with virus replication were observed. Live virus titers in cell supernatants and viral positive- and negative-strand RNA amplification were measured. Amomi extract significantly increased HeLa cell survival in different concentrations (100–10 μg/ml). CVB3 capsid protein VP1 expression (76%) and viral protease 2A-induced eIF4G1 cleavage (70%) were significantly decreased in Amomi extract (100 μg/ml) treated cells. The levels of positive- (20%) and negative-strand (80%) RNA were dramatically decreased compared with the control, as revealed by reverse transcription–PCR. In addition, Amomi extract improved mice survival (51% vs 26%) and dramatically reduced heart inflammation in a CVB3-induced myocarditis mouse model. These results suggested that Amomi extract significantly inhibited Enterovirus replication and myocarditis damage. Amomi may be developed as a therapeutic drug for Enterovirus.
Abstract
Coxsackievirus B3 (CVB3) is the main cause of acute myocarditis and dilated cardiomyopathy. Plant extracts are considered as useful materials to develop new antiviral drugs. We had previously selected candidate plant extracts, which showed anti-inflammatory effects. We examined the antiviral effects by using a HeLa cell survival assay. Among these extracts, we chose the Amomi Cardamomi (Amomi) extract, which showed strong antiviral effect and preserved cell survival in CVB3 infection. We investigated the mechanisms underlying the ability of Amomi extract to inhibit CVB3 infection and replication. HeLa cells were infected by CVB3 with or without Amomi extract. Erk and Akt activities, and their correlation with virus replication were observed. Live virus titers in cell supernatants and viral positive- and negative-strand RNA amplification were measured. Amomi extract significantly increased HeLa cell survival in different concentrations (100–10 μg/ml). CVB3 capsid protein VP1 expression (76%) and viral protease 2A-induced eIF4G1 cleavage (70%) were significantly decreased in Amomi extract (100 μg/ml) treated cells. The levels of positive- (20%) and negative-strand (80%) RNA were dramatically decreased compared with the control, as revealed by reverse transcription–PCR. In addition, Amomi extract improved mice survival (51% vs 26%) and dramatically reduced heart inflammation in a CVB3-induced myocarditis mouse model. These results suggested that Amomi extract significantly inhibited Enterovirus replication and myocarditis damage. Amomi may be developed as a therapeutic drug for Enterovirus.
참고문헌 (30)
- Badorff C, "Enteroviral protease 2A directly cleaves dystrophin and is inhibited by a dystrophin-based substrate analogue", J. Biol. Chem, 275, pp.11191~11197 (2000)
- Chen TC, "Development of antiviral agents for enteroviruses", J. Antimicrob. Chemother, 62, pp.1169~1173 (2008)
- Choi HG, "Anti-allergic inflammatory activities of compounds of amomi fructus", Nat. Prod. Commun, 10, pp.631~632 (2015)
- Esfandiarei M, "Protein kinase B", Akt regulates coxsackievirus B3 replication through a mechanism which is not caspase dependent, 2004, pp.78, 4289~4298
- Feldman AM, "Myocarditis", N. Engl. J. Med, 343, pp.1388~1398 (2000)
- Herskowitz A, "Coxsackievirus B3 murine myocarditis: wide pathologic spectrum in genetically defined inbred strains", Hum. Pathol, 16, pp.671~673 (1985)
- Kearney MT, "Viral myocarditis and dilated cardiomyopathy: mechanisms, manifestations, and management", Postgrad. Med. J, 77, pp.4~10 (2001)
- Kim JM, "TNFR-Fc fusion protein expressed by in vivo electroporation improves survival rates and myocardial injury in coxsackievirus induced murine myocarditis", Biochem. Biophys. Res. Commun, 344, pp.765~771 (2006)
- Knowlton KU, "The immune system in viral myocarditis: maintaining the balance", Circ. Res, 85, pp.559~561 (1999)
- Knowlton KU, "A mutation in the puff region of VP2 attenuates the myocarditic phenotype of an infectious cDNA of the Woodruff variant of coxsackievirus B3", J. Virol, 70, pp.7811~7818 (1996)
- Kumar S, "Chemistry and biological activities of flavonoids: an overview", Scientific World Journal, 2013, pp.162750~ (2013)
- Lim BK, "Local expression of interleukin-1 receptor antagonist by plasmid DNA improves mortality and decreases myocardial inflammation in experimental coxsackieviral myocarditis", Circulation, 105, pp.1278~1281 (2002)
- Lim BK, "Virus receptor trap neutralizes coxsackievirus in experimental murine viral myocarditis", Cardiovasc. Res, 71, pp.517~526 (2006)
- Lim BK, "ORI2 inhibits coxsackievirus replication and myocardial inflammation in experimental murine myocarditis", Biol. Pharm. Bull, 37, pp.1650~1654 (2014)
- Lim BK, "Coxsackievirus B3 replication is related to activation of the late extracellular signal-regulated kinase (ERK) signal", Virus Res, 113, pp.153~157 (2005)
- Lim BK, "Coxsackievirus and adenovirus receptor (CAR) mediates atrioventricular-node function and connexin 45 localization in the murine heart", J. Clin. Invest, 118, pp.2758~2770 (2008)
- Lim BK, "Foreign gene transfer to cardiomyocyte using a replication-defective recombinant coxsackievirus B3 without cytotoxicity", Intervirology, 55, pp.201~209 (2012)
- Lim BK, "Role of the myristoylation site in expressing exogenous functional proteins in coxsackieviral vector", Biosci. Biotechnol. Biochem, 76, pp.1173~1176 (2012)
- Liu P, "Viral myocarditis: balance between viral infection and immune response", Can. J. Cardiol, 12, pp.935~943 (1996)
- Martino TA, "Viral infection and the pathogenesis of dilated cardiomyopathy", Circ. Res, 74, pp.182~188 (1994)
- Schnitzler P, "Antiviral activity and mode of action of propolis extracts and selected compounds", Phytother. Res, 24(Suppl 1), pp.S20~S28 (2010)
- 송재형, "Antiviral Activity of Chrysin Derivatives against Coxsackievirus B3 in vitro and in vivo", Biomolecules & Therapeutics, 23(5), pp.465~470 (2015), 한국응용약물학회
- Sun F, "Differential expression of coxsackievirus and adenovirus receptor on alveolar epithelial cells between fetal and adult mice determines their different susceptibility to coxsackievirus B infection", Arch. Virol, 157, pp.1101~1111 (2012)
- Wang SM, "Update of enterovirus 71 infection:epidemiology, pathogenesis and vaccine", Expert Rev. Anti Infect. Ther, 12, pp.447~456 (2014)
- Wong J, "Cleavage of serum response factor mediated by enteroviral protease 2A contributes to impaired cardiac function", Cell Res, 22, pp.360~371 (2012)
- Woodruff JF, "Viral myocarditis. A review", Am. J. Pathol, 101, pp.425~484 (1980)
- Xiong D, "Dystrophin deficiency markedly increases enterovirus-induced cardiomyopathy: a genetic predisposition to viral heart disease", Nat. Med, 8, pp.872~877 (2002)
- Xiong D, "Inducible cardiac-restricted expression of enteroviral protease 2A is sufficient to induce dilated cardiomyopathy", Circulation, 115, pp.94~102 (2007)
- "Zhongguo Zhong Yao Za Zhi", 1997, 231~232
- Yun SH, "Antiviral activity of coxsackievirus B3 3C protease inhibitor in experimental murine myocarditis", J. Infect. Dis, 205, pp.491~497 (2012)